Walk through any pharmacy or scroll through any wellness feed and you will find the word “peptides” on serums, powders, injections, and supplements. It appears alongside claims about cellular repair, collagen rebuilding, fat burning, and immune reset — often without any explanation of what a peptide actually is or why it would do any of those things.

This article is the foundation for our peptide series. Before evaluating whether any specific peptide product works, it helps to understand what the word means, what the body actually does with peptides, and — most importantly — why the three routes a peptide can take into your body each come with a wall that marketing rarely mentions.

What a Peptide Actually Is

A peptide is a chain of amino acids linked together by peptide bonds — the same chemical bonds that hold proteins together. The only meaningful distinction between a peptide and a protein is length: by convention, chains of roughly 50 amino acids or fewer are called peptides; longer chains are proteins. That boundary is arbitrary and contested, which is worth keeping in mind when a product claims to contain “peptides, not proteins” as though those were categorically different things.

The size spectrum matters in practice. A dipeptide (two amino acids) behaves very differently from a 40-residue polypeptide. Smaller chains are more stable, more likely to survive digestion, and more likely to penetrate certain barriers — but they also carry less structural information and have fewer specific biological effects. Larger peptides can have potent signaling roles but face steeper delivery challenges.

What the Body Uses Peptides For

Your body makes and uses peptides constantly. Some of the most familiar hormones and signaling molecules are peptides: insulin (51 amino acids), oxytocin (9 amino acids), and glucagon-like peptide-1 (GLP-1, 30 amino acids) are all endogenous peptides with well-defined physiological roles. Endorphins — the molecules associated with pain relief and mood — are also peptides.

Peptides function primarily as signals: they bind to receptors on cell surfaces or inside cells and trigger downstream responses. This is why the pharmaceutical industry has invested heavily in synthetic peptides — if you can design a molecule that mimics or blocks an endogenous peptide signal, you have a potential drug. GLP-1 receptor agonists like semaglutide are exactly this: a synthetic peptide engineered to mimic and extend the action of the body’s own GLP-1.

The problem is that “peptides are powerful signaling molecules in the body” is true, but it does not follow that adding peptides to a serum or a capsule replicates those signals. Getting from the product to the receptor is the entire challenge.

The Three Delivery Routes — and Why Each Has a Wall

Topical (Applied to Skin)

Skin is designed to keep things out. The stratum corneum — the outermost layer — acts as a physical barrier that strongly restricts what can penetrate to living tissue below. The well-established rule of thumb in dermatology and cosmetic chemistry is the 500 Dalton rule: molecules with a molecular weight above approximately 500 Da have very limited passive skin penetration. Most cosmetically active peptides have molecular weights of 500–1,500 Da, putting them at or above this threshold.

Some penetration enhancers (alcohols, certain lipid carriers) can improve delivery, and there is evidence that specific short peptides do reach the dermis under optimized conditions. But “some penetration under lab conditions” is not the same as “reaches target cells in sufficient concentration to produce a clinical effect in a consumer product.” The gap between those two statements is where most topical peptide marketing operates.

Oral (Swallowed)

The gastrointestinal tract is a proteolytic environment: it contains enzymes (proteases) whose job is to break peptide bonds. Most dietary and supplemental peptides are digested into individual amino acids or very short fragments before absorption. This is not a flaw — it is how the gut extracts nutrition from protein — but it means an orally ingested peptide typically does not arrive intact at a distant target tissue.

Some short peptides do survive partial digestion and are absorbed as di- or tripeptides via specific intestinal transporters (notably PepT1). Collagen-derived dipeptides such as Pro-Hyp have been detected in blood after oral ingestion, which is the mechanistic basis for the collagen supplement literature. But even absorbed peptides face a second hurdle: first-pass metabolism in the liver, which can clear many bioactive molecules before they reach systemic circulation. This is why semaglutide, a GLP-1 receptor agonist, requires either subcutaneous injection or a specifically engineered oral formulation with an absorption enhancer to work at all.

Injectable (Subcutaneous or Intravenous)

Injection bypasses both the skin barrier and the digestive tract, delivering the peptide directly into circulation. This is why nearly all clinically validated peptide pharmaceuticals are injectable: insulin, semaglutide, teriparatide (a parathyroid hormone peptide for osteoporosis), and most peptide-based cancer treatments are all given by injection or infusion. The delivery wall is effectively removed, which is why the evidence for injectable peptides tends to be stronger — and also why injectable products sold outside the pharmaceutical supply chain carry their own risks around sterility, dosing accuracy, and contaminants.

For a topical product, “directly to your cells” requires the peptide to cross the stratum corneum — and for most peptide sizes, passive penetration is limited. For an oral product, “directly to your cells” requires surviving digestion, being absorbed intact, surviving first-pass metabolism, and reaching target tissue at a concentration sufficient for the claimed effect. The marketing language typically skips all of these steps.

Why “Contains Peptides” on a Label Tells You Almost Nothing

The word “peptides” on a product label provides no information about:

• Which peptide — there are thousands of known bioactive peptides with entirely different mechanisms and targets
• What concentration — a peptide listed near the bottom of an ingredient deck may be present at a fraction of a percent
• Whether it can be delivered — molecular weight, formulation, and route all determine whether the peptide reaches its purported target
• Whether there is human evidence for this specific peptide, at this concentration, via this route

From a regulatory standpoint, most peptide-containing consumer products in the US are sold as cosmetics or dietary supplements rather than drugs. Under the Modernization of Cosmetics Regulation Act (MoCRA), cosmetics cannot claim to alter the structure or function of the body — that crosses into drug territory. The practical result is that peptide marketing uses language that implies physiological change (“rebuilds collagen,” “activates repair”) while technically remaining in cosmetic or supplement territory, where pre-market efficacy proof is not required.

Synthetic vs. “Bioidentical” vs. Naturally Derived

These terms appear frequently in peptide marketing and carry more implication than precision. A “bioidentical” peptide is chemically identical to an endogenous one — same sequence, same structure. This does not mean it works the same way when administered exogenously; it still faces the same delivery walls. “Naturally derived” typically means the peptide was hydrolyzed from a food source (collagen, whey, soy) rather than synthesized chemically — a distinction that has no bearing on efficacy and sometimes obscures that the final molecule is identical to a synthetic version. “Synthetic” is not a negative: most pharmaceutical-grade peptides are synthesized because it allows precise purity, sequence control, and modification (such as adding fatty acid chains to extend half-life, as with semaglutide).

What This Series Covers Next

With this framework in place, the rest of the series examines specific peptide categories where the marketing is loudest and the evidence is most worth scrutinizing:

• AOD-9604 and fat-loss peptide fragments — marketed as a prescription-free alternative to GLP-1 drugs, with a Phase 3 failure the marketing does not mention
• Anti-aging peptides — EGF, FGF, and oral “cellular rejuvenation” products; the gap between cell-culture results and human skin outcomes
• Gut-healing peptides — larazotide, glutamine peptides, and the “leaky gut” crossover
• A practical buyer’s guide — what pharmaceutical-grade means, how to read an ingredient deck, and what questions to ask a prescriber before injecting anything

References & Further Reading

• Bos, J. D., & Meinardi, M. M. H. M. (2000). The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology, 9(3), 165–169.
• Lintner, K., et al. (2009). Cosmetic peptides. American Journal of Clinical Dermatology, 10(6), 347–357.
• Shigemura, Y., et al. (2014). Identification of bioavailable collagen peptides in the blood after oral ingestion of a collagen hydrolysate. Food Chemistry, 159, 328–332.
• U.S. Food & Drug Administration. Modernization of Cosmetics Regulation Act of 2022 (MoCRA).
• Marketing or Science. Beauty Peptides by Class: What the Clinical Evidence Actually Shows.
• Marketing or Science. Oral Collagen Peptides: The Bioavailability Question the Marketing Skips.